CRC
MCID: CLR023
MIFTS: 99

Colorectal Cancer (CRC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 57 38 12 75 37 29 13 13 55 6 43 15 63 73
Colon Cancer 57 12 75 29 55 6 15
Colorectal Carcinoma 12 55 15 73
Colon Carcinoma 12 55 15 73
Carcinoma of Colon 12 29 6
Colonic Adenoma Recurrence, Reduced Risk of 57 6
Colorectal Cancer, Susceptibility to 57 6
Colon Cancer, Susceptibility to 57 6
Colorectal Cancer, Somatic 57 13
Colon Cancer, Somatic 57 13
Colonic Neoplasms 44 73
Crc 57 75
Colon Cancer, Advanced, Somatic 57
Cancer, Colorectal, Somatic 40
Malignant Tumor of Colon 73
Colorectal Neoplasms 73
Cancer, Colorectal 40
Colonic Carcinoma 12

Characteristics:

OMIM:

57
Inheritance:
autosomal dominantly acting oncogene plus loss of suppressor gene(s)


Classifications:



Summaries for Colorectal Cancer

PubMed Health : 63 About colorectal cancer: Colorectal (bowel) cancer is one of the more common forms of cancer in many countries, including Germany. The name "colorectal cancer" is used to describe bowel cancer that starts in the colon (the large intestine) or the rectum. Cancer of the small intestine is very rare.Colorectal cancer almost always develops from growths called colorectal polyps that form in the lining of the colon. But by no means do all polyps become cancerous – and if a polyp does become cancerous, it takes many years. One way to prevent colorectal cancer is to have a colonoscopy, which also allows doctors to remove polyps.Having colorectal cancer can be a life-changing experience. What happens after the diagnosis has been made will depend on various factors, including the stage of the cancer. In early-stage colorectal cancer, the tumor just needs to be surgically removed. In advanced stages, additional treatments may be considered, such as chemotherapy or radiation therapy.In Germany, high-quality medical care is available for people who have cancer. There are also a number of sources of support, for instance to help cope with the disease emotionally and make it easier to go back to work.

MalaCards based summary : Colorectal Cancer, also known as colon cancer, is related to colorectal cancer, hereditary nonpolyposis, type 7 and familial colorectal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Colorectal Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Colorectal cancer and MicroRNAs in cancer. The drugs Avastin and Campostar have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are renal cell carcinoma and neoplasm of the stomach

Disease Ontology : 12 A large intestine cancer that is located in the colon and/or located in the rectum.

OMIM : 57 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500)

MedlinePlus : 43 The colon and rectum are part of the large intestine. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50. You're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or Crohn's disease, eat a diet high in fat, or smoke. Symptoms of colorectal cancer include Diarrhea or constipation A feeling that your bowel does not empty completely Blood (either bright red or very dark) in your stool Stools that are narrower than usual Frequent gas pains or cramps, or feeling full or bloated Weight loss with no known reason Fatigue Nausea or vomiting Because you may not have symptoms at first, it's important to have screening tests. Everyone over 50 should get screened. Tests include colonoscopy and tests for blood in the stool. Treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. Surgery can usually cure it when it is found early. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 75 Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

Wikipedia : 76 Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 758)
# Related Disease Score Top Affiliating Genes
1 colorectal cancer, hereditary nonpolyposis, type 7 34.5 MLH1 MLH3
2 familial colorectal cancer 34.5 APC MLH1 PTPRJ TP53
3 lynch syndrome 34.5 APC CTNNB1 MLH1 MLH3 TP53
4 polyposis syndrome, hereditary mixed, 1 33.6 APC MLH1
5 familial adenomatous polyposis 33.5 MLH1 MCC CTNNB1 AXIN2 APC TP53
6 mismatch repair cancer syndrome 33.1 APC CTNNB1 MLH1
7 colonic disease 32.5 AKT1 CTNNB1 MLH1 TP53
8 colon adenocarcinoma 32.5 APC BAX CTNNB1 MLH1
9 familial adenomatous polyposis 1 32.2 APC CTNNB1
10 adenoma 32.2 APC AXIN2 CTNNB1 MLH1 TP53
11 adenocarcinoma 31.8 AKT1 APC CTNNB1 FGFR3 TP53 PIK3CA
12 endometrial cancer 31.7 AKT1 BAX CTNNB1 MLH1 MLH3 PIK3CA
13 colorectal adenoma 31.7 APC CTNNB1 MLH1 TP53
14 gastric cancer 31.7 AKT1 APC BAX CTNNB1 MLH1 PIK3CA
15 hepatocellular carcinoma 31.6 AKT1 APC BAX CTNNB1 DLC1 NRAS
16 ovarian cancer 31.4 AKT1 BAX CTNNB1 MLH1 PIK3CA TP53
17 cholangiocarcinoma 31.1 AKT1 APC CTNNB1 PIK3CA TP53
18 esophageal cancer 31.0 AKT1 BAX CTNNB1 DCC PIK3CA TP53
19 colorectal adenocarcinoma 31.0 CTNNB1 MLH1 TP53
20 squamous cell carcinoma 31.0 AKT1 CTNNB1 FGFR3 PIK3CA TP53
21 lung cancer susceptibility 3 31.0 AKT1 APC CTNNB1 FGFR3 NRAS PIK3CA
22 hyperplastic polyposis syndrome 30.9 APC TP53
23 adamantinoma of long bones 30.9 APC BAX CTNNB1 MLH1 PIK3CA TP53
24 cervical cancer 30.9 AKT1 BAX CTNNB1 FGFR3 PIK3CA TP53
25 squamous cell carcinoma, head and neck 30.8 AKT1 CTNNB1 FGFR3 PIK3CA TP53
26 lymphoma, non-hodgkin, familial 30.8 BAX NRAS PIK3CA RAD54B TP53
27 gastrointestinal system disease 30.7 AKT1 CTNNB1 MLH1 TP53
28 neuroblastoma 30.7 AKT1 AXIN2 TP53 PIK3CA NRAS FGFR3
29 gallbladder cancer 30.7 AKT1 MLH1 PIK3CA TP53
30 thyroid cancer 30.7 AKT1 APC CTNNB1 NRAS PIK3CA TP53
31 peutz-jeghers syndrome 30.6 APC CTNNB1 TP53
32 intestinal disease 30.6 AKT1 CTNNB1 MLH1 PIK3CA TP53
33 li-fraumeni syndrome 30.5 BAX MLH1 TP53
34 endometrial adenocarcinoma 30.5 AKT1 CTNNB1 MLH1 TP53
35 breast adenocarcinoma 30.5 AKT1 BAX PIK3CA TP53
36 pancreas adenocarcinoma 30.5 AKT1 CTNNB1 PIK3CA TP53
37 serous cystadenocarcinoma 30.5 AKT1 PIK3CA TP53
38 myeloma, multiple 30.4 AKT1 FGFR3 NRAS TP53
39 carcinosarcoma 30.4 CTNNB1 PIK3CA TP53
40 bladder disease 30.4 AKT1 FGFR3 TP53
41 suppression of tumorigenicity 12 30.4 AKT1 CTNNB1 PIK3CA TP53
42 uterine carcinosarcoma 30.3 CTNNB1 PIK3CA TP53
43 cystadenocarcinoma 30.3 AKT1 PIK3CA TP53
44 ovarian cancer 1 30.3 AKT1 PIK3CA TP53
45 anaplastic thyroid cancer 30.2 CTNNB1 PIK3CA TP53
46 colorectal cancer 12 12.6
47 colorectal cancer 1 12.6
48 colorectal cancer 3 12.6
49 colorectal cancer 10 12.6
50 colorectal cancer, hereditary nonpolyposis, type 5 12.6

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 22)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectal Neoplasm
Rectosigmoid Junction Neoplasm Small Intestine Cancer
Splenic Flexure Cancer Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:



Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
hereditary nonpolyposis colorectal carcinoma
associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma
apc, ras, dcc or kras gene mutations
allele loss on chromosomes 5, 6, 12q, 15, 17, 18, or 22


Clinical features from OMIM:

114500

Human phenotypes related to Colorectal Cancer:

32
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 32 HP:0005584
2 neoplasm of the stomach 32 HP:0006753
3 transitional cell carcinoma of the bladder 32 HP:0006740
4 uterine leiomyosarcoma 32 HP:0002891
5 hereditary nonpolyposis colorectal carcinoma 32 HP:0006716

UMLS symptoms related to Colorectal Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.45 PIK3CA
2 Decreased viability GR00221-A-1 10.45 AKT1 FGFR3 PIK3CA NRAS PDGFRL
3 Decreased viability GR00221-A-2 10.45 AKT1 DCC EP300 FGFR3 PIK3CA
4 Decreased viability GR00221-A-3 10.45 AKT1 DCC FGFR3 NRAS
5 Decreased viability GR00221-A-4 10.45 AKT1 DCC PIK3CA
6 Decreased viability GR00402-S-2 10.45 AKT1 DCC EP300 FGFR3 PIK3CA NRAS
7 Decreased ionizing radiation sensitivity GR00232-A-1 9.86 AKT1 AXIN2 EP300 MLH1 NRAS PTPN12
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 AKT1 BAX DCC MLH1 PDGFRL RAD54B
9 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 AKT1 BAX DCC MLH1 PDGFRL RAD54B
10 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BAX EP300 MLH1 MLH3 RAD54B TP53

MGI Mouse Phenotypes related to Colorectal Cancer:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AKT1 APC AXIN2 BAX CTNNB1 DCC
2 hematopoietic system MP:0005397 10.45 AKT1 APC BAX CTNNB1 DCC DLC1
3 mortality/aging MP:0010768 10.44 AKT1 APC AXIN2 BAX CTNNB1 DCC
4 growth/size/body region MP:0005378 10.43 AKT1 APC AXIN2 BAX CTNNB1 DLC1
5 homeostasis/metabolism MP:0005376 10.41 AKT1 APC BAX CTNNB1 DLC1 EP300
6 cardiovascular system MP:0005385 10.4 AKT1 APC AXIN2 CTNNB1 DLC1 EP300
7 immune system MP:0005387 10.4 AKT1 APC BAX CTNNB1 DCC EP300
8 embryo MP:0005380 10.38 AKT1 APC AXIN2 CTNNB1 DLC1 EP300
9 endocrine/exocrine gland MP:0005379 10.33 AKT1 APC AXIN2 BAX CTNNB1 EP300
10 neoplasm MP:0002006 10.29 AKT1 APC BAX CTNNB1 DCC EP300
11 nervous system MP:0003631 10.23 AKT1 APC AXIN2 BAX CTNNB1 DCC
12 craniofacial MP:0005382 10.21 APC AXIN2 CTNNB1 DLC1 EP300 FGFR3
13 digestive/alimentary MP:0005381 10.21 APC CTNNB1 DCC EP300 FGFR3 MLH1
14 integument MP:0010771 10.15 AKT1 APC CTNNB1 FGFR3 MLH1 NRAS
15 normal MP:0002873 10.14 AKT1 APC AXIN2 CTNNB1 DLC1 EP300
16 muscle MP:0005369 10.1 AKT1 APC BAX CTNNB1 EP300 PIK3CA
17 no phenotypic analysis MP:0003012 10.09 APC AXIN2 CTNNB1 FGFR3 NRAS PIK3CA
18 limbs/digits/tail MP:0005371 10.08 APC AXIN2 BAX CTNNB1 FGFR3 NRAS
19 liver/biliary system MP:0005370 10.07 AKT1 APC CTNNB1 NRAS PTPN12 PTPRJ
20 reproductive system MP:0005389 10 AKT1 APC AXIN2 BAX CTNNB1 FGFR3
21 renal/urinary system MP:0005367 9.87 APC BAX CTNNB1 EP300 FGFR3 FLCN
22 respiratory system MP:0005388 9.81 AKT1 BAX CTNNB1 DCC EP300 FGFR3
23 pigmentation MP:0001186 9.77 APC CTNNB1 DCC NRAS TP53
24 skeleton MP:0005390 9.61 AKT1 APC AXIN2 BAX CTNNB1 FGFR3
25 vision/eye MP:0005391 9.36 APC AXIN2 BAX CTNNB1 DCC EP300

Drugs & Therapeutics for Colorectal Cancer

PubMedHealth treatment related to Colorectal Cancer: 63

Surgery is performed to remove as much of the cancer as possible. In early stages, further treatment may not be needed. If the cancer is at a more advanced stage, further treatments like radiation therapy or chemotherapy are options.

FDA approved drugs:

(show all 13)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Avastin 18 49 BEVACIZUMAB Genentech July 2009
2
Campostar 18 49 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
3
CEA-Scan 18 Immunomedics April 1996
4
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
5
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
6
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
7
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
8
Iressa 18 49 GEFITINIB AstraZeneca May 2003
9
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
10
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
11
Vectibix 18 49 PANITUMUMAB Amgen September 2006
12
Xeloda 18 49 CAPECITABINE Roche April 1998/ May 2001
13
Zaltrap 18 49 ZIV-AFLIBERCEPT Sanofi-aventis August 2012

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 958)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 17902-23-7 5386
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
4
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
5
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
6
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
7
Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
8
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112887-68-0 104758
9
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
10
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
11
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
12
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
13
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7553-56-2 807
14
Phytonadione Approved, Investigational Phase 4,Phase 2,Phase 1 84-80-0 4812 5284607
15
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
16
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 137-58-6 3676
17
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
18
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 114-07-8 12560
19
Bisacodyl Approved Phase 4,Phase 3,Not Applicable 603-50-9
20
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
21 tannic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable
22
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
23
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-66-6
24
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 169590-42-5 2662
27
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
28
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
29
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
30
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
31
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
32
Acetaminophen Approved Phase 4,Phase 2,Not Applicable 103-90-2 1983
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 437-38-7 3345
34
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 2078-54-8 4943
35
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
37
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
38
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
39
Ketorolac Approved Phase 4,Phase 2,Not Applicable 66635-83-4, 74103-06-3 3826
40
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
41
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
42
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
43
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
44
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
45
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
46
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
47
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
48
Ferrous fumarate Approved Phase 4 141-01-5
49
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
50
Magnesium citrate Approved Phase 4,Phase 3,Not Applicable 3344-18-1

Interventional clinical trials:

(show top 50) (show all 5572)
# Name Status NCT ID Phase Drugs
1 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
2 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
3 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
4 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
5 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
6 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
7 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
8 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
9 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
10 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
11 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
12 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
13 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
14 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
15 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
16 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
17 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
18 Intravenous Iron for Correction of Anaemia After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
19 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
20 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
21 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
22 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
23 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
24 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
25 A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer Terminated NCT00114946 Phase 4 Avastin
26 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
27 Dissemination of Colorectal Cancer Screening to Primary Care Physicians Completed NCT00441311 Phase 4
28 Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Recruiting NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
29 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
30 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
31 Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). Recruiting NCT03564938 Phase 4 Regorafenib (Stivarga, BAY73-4506)
32 Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
33 Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery Not yet recruiting NCT03700411 Phase 4 Morphine;Piritramid;Epidural
34 Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis? Terminated NCT01740947 Phase 4 Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
35 Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery Not yet recruiting NCT03700541 Phase 4 Morphine;Piritramid
36 Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer Completed NCT00928928 Phase 4
37 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
38 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
39 Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 Terminated NCT01468623 Phase 4
40 Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer Completed NCT00869271 Phase 4
41 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
42 Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
43 Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer Recruiting NCT03645187 Phase 4 FOLFOX;Folfox and celecoxib
44 CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
45 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
46 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
47 Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases Terminated NCT00327093 Phase 4 cetuximab;bevacizumab
48 Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer Completed NCT01493713 Phase 4
49 Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases Recruiting NCT02015923 Phase 4 Chemotherapy- scheme
50 I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer Completed NCT00677586 Phase 4

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Colon 29 AKT1 APC AXIN2 BUB1B CTNNB1 DCC DLC1 EP300 FGFR3 FLCN NRAS PIK3CA SRC TP53
2 Colon Cancer 29
3 Colorectal Cancer 29

Anatomical Context for Colorectal Cancer

MalaCards organs/tissues related to Colorectal Cancer:

41
Colon, Liver, Testes, Breast, Lung, Lymph Node, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Cancer:

19
The Colon, The Rectum

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 16663)
# Title Authors Year
1
PPARδ agonist enhances colitis-associated colorectal cancer. ( 30391747 )
2019
2
Mouse Model of Colitis-Associated Colorectal Cancer (CAC): Isolation and Characterization of Mucosal-Associated Lymphoid Cells. ( 30465204 )
2019
3
Immunoprofiles of colorectal cancer from Lynch syndrome. ( 30546958 )
2019
4
MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells. ( 30551544 )
2019
5
Murine Models of Intraperitoneal Perfusion for Disseminated Colorectal Cancer. ( 30502264 )
2019
6
The Tumor Suppressor SASH1 Interacts With the Signal Adaptor CRKL to Inhibit Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. ( 30480076 )
2019
7
Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review. ( 30481373 )
2019
8
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). ( 30496943 )
2019
9
Invitees do not adequately act on alarm symptoms in colorectal cancer screening with fecal immunochemical tests. ( 30507642 )
2019
10
Colorectal Cancer Screening: Is Colonoscopy the Best Option? ( 30466668 )
2019
11
Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway. ( 30468657 )
2019
12
Astragaloside IV inhibits human colorectal cancer cell growth. ( 30468676 )
2019
13
Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. ( 30471650 )
2019
14
Long non-coding RNA TP73‑AS1 promotes colorectal cancer proliferation by acting as a ceRNA for miR‑103 to regulate PTEN expression. ( 30472379 )
2019
15
Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. ( 30476731 )
2019
16
Autophagy induced by ionizing radiation promotes cell death over survival in human colorectal cancer cells. ( 30412717 )
2019
17
Long interspersed nucleotide element-1 (LINE-1) methylation in colorectal cancer. ( 30445031 )
2019
18
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. ( 30384048 )
2019
19
Folic acid inhibits colorectal cancer cell migration. ( 30393128 )
2019
20
HIF-1α-induced miR-23a∼27a∼24 cluster promotes colorectal cancer progression via reprogramming metabolism. ( 30393198 )
2019
21
ErbB4/KITENIN-Mediated Signaling is Activated in Cetuximab-Resistant Colorectal Cancer Cells. ( 30360226 )
2019
22
MicroRNA-296 inhibits colorectal cancer cell growth and enhances apoptosis by targeting ARRB1-mediated AKT activation. ( 30365090 )
2019
23
Sphingosine kinase 1 promotes the metastasis of colorectal cancer by inducing the epithelial‑mesenchymal transition mediated by the FAK/AKT/MMPs axis. ( 30365116 )
2019
24
Galla Rhois water extract inhibits lung metastasis by inducing AMPK‑mediated apoptosis and suppressing metastatic properties of colorectal cancer cells. ( 30365120 )
2019
25
PEA15 promotes liver metastasis of colorectal cancer by upregulating the ERK/MAPK signaling pathway. ( 30365128 )
2019
26
Downregulation of cyclooxygenase‑1 stimulates mitochondrial apoptosis through the NF‑κB signaling pathway in colorectal cancer cells. ( 30320345 )
2019
27
Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc. ( 30343112 )
2019
28
Association of PARK2 promoter polymorphisms and methylation with colorectal cancer in North Indian population. ( 30296568 )
2019
29
Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway. ( 30312725 )
2019
30
Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer. ( 30551398 )
2019
31
MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells. ( 30551403 )
2019
32
Establishment of in vitro and in vivo anti-colon cancer efficacy of essential oils containing oleo-gum resin extract of Mesua ferrea. ( 30551416 )
2019
33
Long non-coding RNA HULC interacts with miR-613 to regulate colon cancer growth and metastasis through targeting RTKN. ( 30551459 )
2019
34
Raster-scan optoacoustic angiography of blood vessel development in colon cancer models. ( 30555784 )
2019
35
A Foodomics Approach: CE-MS for Comparative Metabolomics of Colon Cancer Cells Treated with Dietary Polyphenols. ( 30426427 )
2019
36
Potent Anti-Proliferation on the Colon Cancer Cell Line (HT-29) of Liposomal Formulations Entrapped with Semi-Purified Job's Tears (Coix lacryma-jobi Linn.) Fractions. ( 30486940 )
2019
37
COMP Gene Coexpresses With EMT Genes and Is Associated With Poor Survival in Colon Cancer Patients. ( 30502262 )
2019
38
Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases. ( 30502288 )
2019
39
Failure to Rescue in Postoperative Patients With Colon Cancer: Time to Rethink Where You Get Surgery. ( 30527459 )
2019
40
Robotic Radical Surgery in the Multidisciplinary Approach for the Treatment of Locally Advanced T4 Rectosigmoid Colon Cancer. ( 30531267 )
2019
41
Microcystin-LR promotes migration via the cooperation between microRNA-221/PTEN and STAT3 signal pathway in colon cancer cell line DLD-1. ( 30312888 )
2019
42
Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway. ( 30387805 )
2019
43
FAPP2 promotes tumor cell growth in human colon cancer through activation of Wnt signaling. ( 30408464 )
2019
44
Serine/threonine kinase 31 promotes PDCD5-mediated apoptosis in p53-dependent human colon cancer cells. ( 30144069 )
2019
45
Mechanisms of action of vitamin D in colon cancer. ( 29981368 )
2019
46
The mechanisms and clinical significance of PDCD4 in colorectal cancer. ( 30243936 )
2019
47
Zerumbone, a Cyclic Sesquiterpene from Zingiber zerumbet Induces Apoptosis, Cell Cycle Arrest, and Antimigratory Effects in SW480 Colorectal Cancer Cells. ( 29276946 )
2018
48
Family history of colorectal cancer in first-degree relatives and metachronous colorectal adenoma. ( 29463834 )
2018
49
The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. ( 29115526 )
2018
50
MicroRNAs as novel biomarkers for colorectal cancer: New outlooks. ( 29156521 )
2018